Movement Disorders Program, Butler Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA. Tel.: +1 401 455 6669; Fax: +1 401 455 6670; E-mail:
Behav Neurol. 2013 Jan 1;27(4):469-77. doi: 10.3233/BEN-129016.
Psychotic symptoms are common in drug treated patients with Parkinson's disease (PD). Visual hallucinations occur in about 30% and delusions, typically paranoid in nature, occur in about 5%. These problems, particularly the delusions, cause great distress for patient and caregivers, and are among the most important precipitants for nursing home placement. Psychotic symptoms carry a poor prognosis. They often herald dementia, and are associated with increased mortality. These symptoms often abate with medication reductions, but this may not be tolerated due to worsened motor function. Only clozapine has level A evidence to support its use in PD patients with psychosis (PDP), whether demented or not. While quetiapine has been recommended by the American Academy of Neurology for "consideration," double blind placebo controlled trials have demonstrated safety but not efficacy. Other antipsychotic drugs have been reported to worsen motor function and data on the effectiveness of cholinesterase inhibitors is limited. PDP remains a serious problem with limited treatment options.
精神病症状在帕金森病(PD)的药物治疗患者中很常见。约有 30%的患者出现幻觉,约 5%的患者出现妄想,通常是偏执性质的。这些问题,特别是妄想,给患者和护理人员带来了极大的痛苦,是导致入住养老院的最重要的诱因之一。精神病症状预后不良。它们常常预示着痴呆,并与死亡率增加有关。这些症状通常随着药物剂量的减少而减轻,但由于运动功能恶化,可能无法耐受。只有氯氮平具有 A 级证据支持其在伴有精神病(PDP)的 PD 患者中的使用,无论是否痴呆。虽然美国神经病学学会推荐使用喹硫平,但双盲安慰剂对照试验仅证明了其安全性,而没有证明其疗效。其他抗精神病药物已被报道会恶化运动功能,而关于胆碱酯酶抑制剂有效性的数据有限。PDP 仍然是一个严重的问题,治疗选择有限。